{"filing":{"accession_number":"0001628280-26-053308","cik":"0001347178","ticker":"VNDA","company_name":"Vanda Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"vnda-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda-20260805.htm"},"events":[{"id":24955,"run_id":22625,"accession_number":"0001628280-26-053308","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This Item 2.02 disclosure announces Vanda's second quarter 2026 financial results, including net product sales of $50.5 million, net loss of $62.5 million, and cash position of $170.0 million, along with full-year 2026 revenue guidance of $240–$290 million. The press release (Exhibit 99.1) provides detailed quarterly and year-to-date financial performance, product-specific revenue breakdowns, and operational highlights. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational performance.","company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25665,"accession_number":"0001628280-26-053308","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This Item 2.02 disclosure announces Vanda's second quarter 2026 financial results, including net product sales of $50.5 million, net loss of $62.5 million, and cash position of $170.0 million, along with full-year 2026 revenue guidance of $240–$290 million. The press release (Exhibit 99.1) provides detailed quarterly and year-to-date financial performance, product-specific revenue breakdowns, and operational highlights. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:38:24.209536+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25665,"accession_number":"0001628280-26-053308","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This Item 2.02 disclosure announces Vanda's second quarter 2026 financial results, including net product sales of $50.5 million, net loss of $62.5 million, and cash position of $170.0 million, along with full-year 2026 revenue guidance of $240–$290 million. The press release (Exhibit 99.1) provides detailed quarterly and year-to-date financial performance, product-specific revenue breakdowns, and operational highlights. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:38:24.209536+00:00","company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","filing_date":"2026-08-05"}]}